Clinical Trial Update: A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating LY03020 for efficacy and safety in acutely psychotic participants with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• LY03020

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Schizophrenia | Phase 2 | Status: NOT_YET_RECRUITING